Hybrid interferon/interferon tau proteins, compositions and methods of use
US7232563B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 12, 2002 |
| Grant date | Jun 19, 2007 |
| Priority date | — |
| Expiry date | Jun 11, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to hybrid interferon fusion proteins formed of an interferon-α protein where the C-terminal region of the interferon-α protein is replaced by a C-terminal region of interferon-τ. Also described are nucleic acid sequences encoding the interferon fusion proteins, expression vectors containing such sequences, and therapeutic applications of the interferon fusion proteins. The therapeutic applications include antiviral, anticellular proliferation, and anti-inflammatory applications. One advantage of the interferon fusion polypeptides of the present invention is that they have lower cytotoxic side effects when used to treat cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.